Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis.
Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults
The Buck Institute for Research on Aging has received a $3.5 million federal grant to lead the first-ever double-blind, randomized, placebo-controlled clinical trial to understand